GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Pharmaceutical Group Co Ltd (SHSE:600664) » Definitions » COGS-to-Revenue

Harbin Pharmaceutical Group Co (SHSE:600664) COGS-to-Revenue : 0.72 (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Harbin Pharmaceutical Group Co COGS-to-Revenue?

Harbin Pharmaceutical Group Co's Cost of Goods Sold for the three months ended in Mar. 2024 was ¥2,966 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥4,142 Mil.

Harbin Pharmaceutical Group Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.72.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Harbin Pharmaceutical Group Co's Gross Margin % for the three months ended in Mar. 2024 was 28.40%.

Harbin Pharmaceutical Group Co COGS-to-Revenue Historical Data

The historical data trend for Harbin Pharmaceutical Group Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Pharmaceutical Group Co COGS-to-Revenue Chart

Harbin Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 0.78 0.76 0.75 0.74

Harbin Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.75 0.74 0.71 0.72

Harbin Pharmaceutical Group Co COGS-to-Revenue Calculation

Harbin Pharmaceutical Group Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=11404.77 / 15456.578
=0.74

Harbin Pharmaceutical Group Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2965.588 / 4142.161
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harbin Pharmaceutical Group Co  (SHSE:600664) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Harbin Pharmaceutical Group Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 2965.588 / 4142.161
=28.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Harbin Pharmaceutical Group Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Harbin Pharmaceutical Group Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Harbin Pharmaceutical Group Co (SHSE:600664) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Pharmaceutical Group Co Ltd (SHSE:600664) » Definitions » COGS-to-Revenue
Comparable Companies
SZSE:300119 SZSE:002550 SHSE:600789 SZSE:002581 SZSE:002390 SHSE:603367 SZSE:000915 SZSE:002219 SZSE:300702 SZSE:002880 XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
N/A
Address
Xi'an Street West, People 's Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Website
http://www.hayao.com
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
Executives
Lin Guo Ren senior management
Wang Hai Sheng senior management
Liu Bo senior management
Meng Xiao Dong senior management
Xu Hai Ying Directors, senior managers
Liang Chen senior management
Wang Peng Hao senior management
Xiao Qiang senior management
Wei Shuang Ying senior management
Zhou Xing senior management
Bian Ke Supervisors
Sha Mei senior management
Jian Shi Hui Zhu Xi Supervisors
Wang Zhi Fu Supervisors
Jiang Lu Director

Harbin Pharmaceutical Group Co (SHSE:600664) Headlines

No Headlines